Advertisement

Drugs

, Volume 37, Supplement 1, pp 19–22 | Cite as

The Effect of Nedocromil Sodium on Human Eosinophil Activation

  • R. Moqbel
  • O. Cromwell
  • AB. Kay
Section 1: In Vitro Effects of Nedocromil Sodium on Tissues

Summary

Nedocromil sodium inhibited the increase in eosinophil activation (measured by IgG- and complement-dependent cytotoxicity assays) induced by platelet activating factor (PAF). Inhibition of the upregulation in eosinophil effector function by nedocromil sodium was dose-dependent (optimal at 10− 7 mol/L) and paralleled that produced by a specific PAF antagonist, BN 52021. In addition, preliminary data suggest that nedocromil sodium can inhibit the increase in IgG-dependent release of LTC4 from human eosinophils after stimulation with the synthetic tripeptide, formyl-methionyl-leucyl-phenylalanine (fMLP). These data support our previous hypothesis that part of the mode of action of nedocromil sodium may be due to its ability to directly block the chemotactic factor-induced enhancement of inflammatory cell activity.

Keywords

Platelet Activate Factor Cromoglycate Sodium Cromoglycate Schistosoma Mansoni Nedocromil Sodium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anwar ARE, McKean JR, Smithers SR, Kay AB. Human eosinophil- and neutrophil-mediated killing of schistosomula of Schistosoma mansoni in vitro. 1. Enhancement of complement-dependent damage by mast cell-derived mediators and formyl methionyl peptides. Journal of Immunology 124: 1122–1129, 1980Google Scholar
  2. Kay AB, Glass EJ, Salter DMcG. Leucoattractants enhance complement receptors on human phagocytic cells. Clinical and Experimental Immunology 38: 294–299, 1979PubMedGoogle Scholar
  3. Kay AB, Walsh GM, Moqbel R, MacDonald AJ, Nagakura T, et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. Journal of Allergy and Clinical Immunology 80: 1–8, 1987PubMedCrossRefGoogle Scholar
  4. Kurihara K, Wardlaw AJ, Moqbel R, Kay AB. Inhibition of platelet activating factor (PAF)-induced chemotaxis, and PAF binding to human eosinophils and neutrophils by the specific gingkolide-derived PAF antagonist, BN 52021. Journal of Allergy and Clinical Immunology, in press Moqbel R, Sass-Kuhn SP, Goetzl EJ, Kay AB. Enhancement of neutrophil- and eosinophil-mediated complement-dependent killing of schistosomula of Schistosoma mansoni in vitro by leukotriene B4. Clinical and Experimental Immunology 52: 519–527, 1983Google Scholar
  5. Moqbel R, Walsh GM, MacDonald AJ, Kay AB. The effect of disodium cromoglycate on activation of human eosinophils and neutrophils following reversed (anti-IgE) anaphylaxis. Clinical Allergy 16: 73–84, 1986PubMedCrossRefGoogle Scholar
  6. Moqbel R, Cromwell O, Walsh GM, Wardlaw AJ, Kurlak L, Kay AB. The effects of nedocromil sodium (Tilade®) on activation of human eosinophils, neutrophils and histamine release from mast cells. Allergy 43: 268–276,1988.PubMedCrossRefGoogle Scholar
  7. Richerson HB, Walsh GM, Walport MJ, Moqbel R, Kay AB. Enhancement of complement receptors: a comparison of the rosette technique with the uptake of radio-labelled anti-CRl monoclonal antibody. Clinical and Experimental Immunology 62: 442–448, 1985PubMedGoogle Scholar
  8. Shaw RJ, Walsh GM, Cromwell O, Moqbel R, Spry CJF, Kay AB. Activated human eosinophils generate SRS-A leukotrienes following physiological (IgG-dependent) stimulation. Nature 316: 150–152, 1985PubMedCrossRefGoogle Scholar
  9. Walsh GM, Moqbel R, Wardlaw AJ, Kay AB. In vitro effects of chemotactic factors on eosinophil Fc and complement receptor expression. Acta Paediatrica Japonica 29: 672–677, 1987PubMedCrossRefGoogle Scholar
  10. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. Journal of Clinical Investigation 78: 1701–1706, 1986PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • R. Moqbel
    • 1
  • O. Cromwell
    • 1
  • AB. Kay
    • 1
  1. 1.Department of Allergy and Clinical ImmunologyNational Heart and Lung InstituteLondonUnited Kingdom

Personalised recommendations